XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Investment in Surface Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables) - Surface Pharmaceuticals Inc [Member]

3 Months Ended

Mar. 31, 2019

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Surface is summarized below:

		For the
		Three Months Ended
		March 31, 2019
Revenues, net		$	-
Loss from operations			812
Net loss		$	(812	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Surface is summarized below:

		March 31,
		2019
Current assets		$	18,742
Non current assets			49
Total assets		$	18,791
Total liabilities		$	396
Total stockholders’ equity			18,395
Total liabilities and stockholders’ equity		$	18,791

X

- Definition

Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10

+ Details

Name:	srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix:	srt_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: